108 related articles for article (PubMed ID: 8137210)
1. OVX1 as a marker for early stage endometrial carcinoma.
Xu FJ; Yu YH; Daly L; Anselmino L; Hass GM; Berchuck A; Rodriguez GC; Soper JT; Clarke-Pearson DL; Hollis D
Cancer; 1994 Apr; 73(7):1855-8. PubMed ID: 8137210
[TBL] [Abstract][Full Text] [Related]
2. Is OVX1 a suitable marker for endometrial cancer?
Beck EP; Wagner M; Anselmino L; Xu F; Bast RC; Jaeger W
Gynecol Oncol; 1997 May; 65(2):291-6. PubMed ID: 9159340
[TBL] [Abstract][Full Text] [Related]
3. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
4. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
5. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Bast RC; Hacker NF
Cancer; 2001 Dec; 92(11):2837-44. PubMed ID: 11753957
[TBL] [Abstract][Full Text] [Related]
6. OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders.
Martell RE; Xu FJ; Davis WZ; Anselmino L; Yu YH; Daly L; Bast RC
Int J Biol Markers; 1998; 13(3):145-9. PubMed ID: 10079388
[TBL] [Abstract][Full Text] [Related]
7. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass.
Hogdall EV; Høgdall CK; Tingulstad S; Hagen B; Nustad K; Xu FJ; Bast RC; Jacobs IJ
Int J Cancer; 2000 Nov; 89(6):519-23. PubMed ID: 11102897
[TBL] [Abstract][Full Text] [Related]
8. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies.
Suzuki M; Ohwada M; Sato I; Nagatomo M
Oncology; 1995; 52(2):128-33. PubMed ID: 7854772
[TBL] [Abstract][Full Text] [Related]
9. Serum Sialyl-Tn (STN) as a Tumor Marker in Patients with Endometrial Cancer.
Hashiguchi Y; Kasai M; Fukuda T; Ichimura T; Yasui T; Sumi T
Pathol Oncol Res; 2016 Jul; 22(3):501-4. PubMed ID: 26678075
[TBL] [Abstract][Full Text] [Related]
10. Preoperative CA 125 tumour marker in endometrial cancer: correlation with advanced stage disease.
Sebastianelli A; Renaud MC; Grégoire J; Roy M; Plante M
J Obstet Gynaecol Can; 2010 Sep; 32(9):856-860. PubMed ID: 21050518
[TBL] [Abstract][Full Text] [Related]
11. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer.
Xu FJ; Ramakrishnan S; Daly L; Soper JT; Berchuck A; Clarke-Pearson D; Bast RC
Am J Obstet Gynecol; 1991 Nov; 165(5 Pt 1):1356-62. PubMed ID: 1957862
[TBL] [Abstract][Full Text] [Related]
12. Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer.
Olt G; Soper J; Ramakrishnan S; Xu F; Berchuck A; Clarke-Pearson D; Dodge R; Bast RC
Am J Obstet Gynecol; 1996 Apr; 174(4):1316-9. PubMed ID: 8623863
[TBL] [Abstract][Full Text] [Related]
13. Serum carbohydrate antigen elevations in endometrial adenocarcinomas: characterization of DU-PAN-2 expression as a tumor marker.
Yasuda M; Saito K; Kobayashi Y; Muramatsu T; Miyamoto T; Murakami M; Shinozuka T; Ishizuka B; Makino T; Kajiwara H; Osamura RY
J Obstet Gynaecol Res; 2004 Feb; 30(1):59-64. PubMed ID: 14718023
[TBL] [Abstract][Full Text] [Related]
14. The Value of Preoperative CA 125 Levels in Prediction of Myometrial Invasion in Patients with Early-stage Endometrioid- type Endometrial Cancer.
Atguden Z; Yildiz A; Aksut H; Yalcin SE; Yalcin Y; Uysal D; Yetimalar H
Asian Pac J Cancer Prev; 2016; 17(2):497-501. PubMed ID: 26925634
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
[TBL] [Abstract][Full Text] [Related]
16. Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data.
Ferdeghini M; Gadducci A; Prontera C; Marrai R; Malagnino G; Annicchiarico C; Fioretti P; Bianchi R
Anticancer Res; 1993; 13(3):709-13. PubMed ID: 8317901
[TBL] [Abstract][Full Text] [Related]
17. Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma.
Scambia G; Gadducci A; Panici PB; Foti E; Ferdeghini M; Ferrandina G; Amoroso M; Castellani C; Facchini V; Mancuso S
Gynecol Oncol; 1994 Sep; 54(3):292-7. PubMed ID: 8088605
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Gacuta E; Szmitkowski M; Chrostek L; Ławicki S
Tumour Biol; 2018 Jul; 40(7):1010428318790363. PubMed ID: 30052166
[TBL] [Abstract][Full Text] [Related]
20. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
